Email Alert | RSS

Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (3): 289-293.doi: 10.19982/j.issn.1000-6621.20210561

• Clinical Case Discussion • Previous Articles     Next Articles

Analysis of diagnosis and treatment for a pulmonary lymphangitic carcinomatosis misdiagnosed as pulmonary tuberculosis caused by false positive molecular biological test

YANG Cheng-qing1, MEI Chun-lin1, DU Rong-hui1(), LEI Mei2, QIN Li-xin3   

  1. 1Department of Pulmonary and Critical Care Mdicine,Wuhan Pulmonary Hospital,Wuhan 430030,China
    2Department of Pathology,Wuhan Pulmonary Hospital,Wuhan 430030,China
    3Department of Radiology,Wuhan Pulmonary Hospital,Wuhan 430030,China
  • Received:2021-09-18 Online:2022-03-10 Published:2022-03-08
  • Contact: DU Rong-hui E-mail:bluesearh006@sina.com
  • Supported by:
    Health Commission of Hubei Province Scientific Research Project(WJ2019H320);Wuhan Medical Research Project(WX19A05);Wuhan Municipal Health Commission Medical Talent Training Project(201987)

Abstract:

On April 17, 2019, a 69-year-old male patient with pulmonary lymphangitic carcinomatosis was admitted to the Respiratory Department of Wuhan Pulmonary Hospital,and diagnosed as pulmonary tuberculosis due to the positive tuberculosis molecular biological result in other hospital. The patient was hospitalized because of “pulmonary shadow for 3 months and intermittent cough for 2 months”. He had previously been diagnosed with colon cancer. Chest CT scan revealed diffusing nodules along bronchovascular bundles with ground glass shadows, interlobular septal thickening, bilateral hilar and mediastinal lymph node enlargement and bilateral pleural effusion. In bronchoalveolar lavage fluid (BALF), MTB (extremely low) was detected by GeneXpert MTB/RIF (referred to as “GeneXpert”) and MTB was detected by TB-PCR in previous hospital. Therefore, he was diagnosed as tuberculosis, then transferred to Wuhan Pulmonary Hospital. After admission, relevant examinations were completed. PPD skin test and interferon gamma release test was negative, and chest CT imaging features were not consistent with pulmonary tuberculosis. We suspected it was a false positive molecular biological result. Therefore, GeneXpert and tracheal endoscopic ultrasound-guided needle aspiration biopsy (EBUS-TBNA) were recommended. However, the patient refused. The doctor performed a pleural puncture for diagnosis, and 20 ml pleural effusion was extracted. The examination showed that the carcinoembryonic antigen (118.4 μg/L) was significantly elevated, indicating malignant pleural effusion. Finally, medical thoracoscopic pleural biopsy revealed metastatic poorly differentiated adenocarcinoma. Combined with chest CT findings, the patient was diagnosed as pulmonary lymphangitic carcinomatosis who later died due to deterioration of his condition. Therefore, the authors suggest that radiographic findings of nodules along the bronchovascular bundle with thickening of interlobular septa and mediastinal lymph node enlargement should be considered as pulmonary lymphangitic carcinomatosis for differential diagnosis. When imaging findings are not consistent with tuberculosis and molecular biological test is positive, we should be cautious about diagnosing tuberculosis to avoid misdiagnosis and mistreatment.

Key words: Tuberculosis, Pulmonary lymphangitic carcinomatosis, Molecular biology, Diagnosis

CLC Number: